{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:35:08Z","timestamp":1791164108756,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.seminoncol.2006.01.027","type":"journal-article","created":{"date-parts":[[2006,5,22]],"date-time":"2006-05-22T13:06:25Z","timestamp":1148303185000},"page":"29-35","source":"Crossref","is-referenced-by-count":50,"special_numbering":"S5","title":["Strategies in the Management of Alemtuzumab-Related Side Effects"],"prefix":"10.1053","volume":"33","author":[{"given":"Anders","family":"\u00d6sterborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Lundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Mellstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2006.01.027_bib1","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib2","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2001.19.16.3611","article-title":"Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia","volume":"19","author":"Morrison","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib3","first-page":"2723","article-title":"Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia","volume":"96","author":"Robak","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"Anaissie","year":"1998","journal-title":"Ann Intern Med"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.01.027_bib5","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1385\/MO:19:2S:S11","article-title":"Current and developing chemotherapy for CLL","volume":"19","author":"Montserrat","year":"2002","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib6","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V98.8.2319","article-title":"Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients","volume":"98","author":"Leporrier","year":"2001","journal-title":"Blood"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2006.01.027_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1385\/MO:19:2S:S03","article-title":"A personal history of the CAMPATH-1H antibody","volume":"19","author":"Waldmann","year":"2002","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib8","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib9","first-page":"3165","article-title":"Patients with refractory B-CLL and T-PLL treated with alemtuzumab (CamPath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial","volume":"100","author":"Rai","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib10","doi-asserted-by":"crossref","first-page":"573s","DOI":"10.1200\/jco.2004.22.14_suppl.6563","article-title":"Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL)","volume":"22","author":"Robak","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib11","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib12","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H","volume":"98","author":"Wing","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib13","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib14","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro","volume":"100","author":"Rose","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib16","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.027_bib17","first-page":"S93","article-title":"Subcutaneous alemtuzumab without dose escalation in patients with previously treated B-cell chronic lymphocytic leukemia","volume":"46","author":"Lundin","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood.V104.11.478.478","article-title":"Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL","volume":"104","author":"Stilgenbauer","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath-1H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/146532400539008","article-title":"Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G","volume":"2","author":"Williams","year":"2000","journal-title":"Cytotherapy"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib21","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib22","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","article-title":"Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia","volume":"23","author":"Elter","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib23","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/CLM.2004.n.002","article-title":"Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia","volume":"4","author":"Keating","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/sj.leu.2403258","article-title":"Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia","volume":"18","author":"Lundin","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib25","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib26","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/cncr.0680","article-title":"Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"94","author":"Perkins","year":"2002","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","article-title":"Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)","volume":"18","author":"Wendtner","year":"2004","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2006.01.027_bib28","first-page":"93","article-title":"Consolidation with alemtuzumab after a response to fludarabine in patients with CLL","volume":"46","author":"Montillo","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","article-title":"Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"3","author":"Nguyen","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib30","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phase II study of alemtuzumab in chronic lymphoproliferative disorders","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1385\/MO:19:4:277","article-title":"Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"19","author":"Cavalli-Bjorkman","year":"2002","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2249.1992.tb06421.x","article-title":"Humanized monoclonal antibody CAMPATH-1H","volume":"87","author":"Crowe","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib33","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0140-6736(92)92294-P","article-title":"Humanised monoclonal antibody therapy for rheumatoid arthritis","volume":"340","author":"Isaacs","year":"1992","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib34","first-page":"1031","article-title":"Subcutaneous administration of CAMPATH-1H","volume":"24","author":"Schnitzer","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1053\/j.seminoncol.2006.01.027_bib35","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406000595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775406000595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:11:31Z","timestamp":1586909491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775406000595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":35,"alternative-id":["S0093775406000595"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2006.01.027","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}